natgillin/translations-raw huggingface dataset:
In study C2305, grade 3 elevated fasting glucose levels were reported in 9.7% and 0.6% and grade 4 in 0.6% and 0% of acromegaly patients treated with pasireotide intramuscular use and octreotide intramuscular use, respectively. 
U ispitivanju C2305, povišene razine glukoze natašte stupnja 3 bile su prijavljene u 9,7% odnosno 0,6% te stupnja 4 u 0,6% odnosno 0% bolesnika s akromegalijom liječenih pasireotidom primijenjenim intramuskularno odnosno oktreotidom primijenjenim intramuskularno.
Glucose metabolism 
Metabolizam glukoze
No studies have been conducted to evaluate the bioavailability of pasireotide in humans. 
Nisu provedena ispitivanja za procjenu bioraspoloživosti pasireotida kod ljudi.
Glycosylated haemoglobin increased, alanine aminotransferase increased, aspartate aminotransferase increased, gammaglutamyltransferase increased, blood glucose increased, blood creatine phosphokinase increased, lipase increased 
Povišenje glikiranog hemoglobina, povišena alanin aminotransferaza, povišena aspartat aminotransferaza, povišena gamaglutamiltransferaza, povišena glukoza u krvi, povišena kreatin fosfokinaza u krvi, povišena lipaza
Rare cases of concurrent elevations in ALT (alanine aminotransferase) greater than 3 x ULN and bilirubin greater than 2 x ULN have also been observed (see section 4.8). 
Bili su uočeni i rijetki slučajevi istodobnih povišenja ALT-a (alanin aminotransferaze) većih od 3 x gornje granice normale (GGN) te bilirubina većih od 2 x GGN (vidjeti dio 4.8).
Acromegaly is caused by a type of tumour called a pituitary adenoma which develops in the pituitary gland at the base of the brain. 
Akromegalija je uzrokovana vrstom tumora koji se naziva adenom hipofize koji se razvija u hipofizi (žlijezdi koja se nalazi na donjoj strani mozga).
Sinus bradycardia*, QT prolongation 
Sinusna bradikardija*, produženje QT intervala
Also contains: Mannitol, tartaric acid, sodium hydroxide, water for injections. 
Također sadrži: manitol, tartaratnu kiselinu, natrijev hidroksid, vodu za injekcije.
GH <2.5 μg/l and IGF-1 ≤ULN Normalised IGF-1 
GH <2,5 μg/l i IGF-1 ≤GGN Normalizirani IGF-1
Your doctor or nurse will have instructed you on how to use Signifor ampoules. 
Vaš liječnik ili medicinska sestra dati će Vam upute kako primjenjivati ampule Signifora.
At month 7, a mUFC response was achieved in 41.9% and 40.8% of patients randomised to starting doses of 10 mg and 30 mg, respectively. 
U 7. mjesecu odgovor mUFC postiglo je 41,9% bolesnika randomiziranih na početnu dozu od 10 mg, te 40,8% bolesnika randomiziranih na početnu dozu od 30 mg.
- The other ingredients are mannitol, tartaric acid, sodium hydroxide and water for injections. 
- Drugi sastojci su manitol, tartaratna kiselina, natrijev hidroksid i voda za injekcije.
Sites showing signs of inflammation or irritation should be avoided. 
Treba izbjegavati mjesta na kojima su vidljivi znakovi upale ili nadražaja.
Hypocortisolism 
Hipokortizolizam
Pasireotide did not affect fertility in male rats but, as expected from the pharmacology of pasireotide, females presented abnormal cycles or acyclicity, and decreased numbers of corpora lutea and implantation sites. 
Pasireotid nije utjecao na plodnost u mužjaka štakora, ali, kako se i očekuje iz farmakologije pasireotida, ženke su imale abnormalne cikluse ili ih nisu imale te su imale smanjene broja žutih tijela i mjesta implantacije.
Powder and solvent for suspension for injection (powder for injection). 
Prašak i otapalo za suspenziju za injekciju (prašak za injekciju).
If such a switch should be required, the recommended initial dose for the treatment of Cushing's disease is 10 mg of pasireotide by deep intramuscular injection every 4 weeks. 
Ako je takav prelazak potreban, preporučena početna doza u liječenju Cushingove bolesti je 10 mg pasireotida dubokom intramuskularnom injekcijom svakih 4 tjedna.
In the pivotal study with patients inadequately controlled on another somatostatin analogue, the proportion of patients not previously treated with anti-diabetic agents who required commencement of anti-diabetic therapy during the study was 17.5% and 16.1% in the Signifor 40 mg and 60 mg arms compared to 1.5% in the active control arm. 
U ključnom ispitivanju s bolesnicima čije je stanje bilo neodgovarajuće kontrolirano drugim analogom somatostatina, udio bolesnika koji prethodno nisu bili liječeni antidijabeticima i u kojih je bilo potrebno započeti terapiju antidijabetikom tijekom ispitivanja bio je 17,5%, odnosno 16,1%, u skupinama koje su primale Signifor 40 mg, odnosno 60 mg, u usporedbi s 1,5% u skupini s aktivnom kontrolom.
Cushing's disease patients with poor glycaemic control (as defined by HbA1c values >8% while receiving antidiabetic therapy) may be at higher risk of developing severe hyperglycaemia and associated complications (e.g. ketoacidosis). 
Bolesnici oboljeli od Cushingove bolesti sa slabom glikemijskom kontrolom (definiranom vrijednostima HbA1c >8% dok primaju antidijabetičku terapiju) mogli bi imati veći rizik od razvoja teške hiperglikemije i povezanih komplikacija (npr. ketoacidoza).
Health-related quality of life measured by AcroQol indicated statistically significant improvements from baseline to week 24 in the Physical, Psychological-Appearance and Global scores for the 60 mg group and the Physical sub-score for the 40mg group. 
Kvaliteta života povezana sa zdravljem mjerena upitnikom AcroQol ukazala je na statistička značajna poboljšanja od početne vrijednosti do 24. tjedna u rezultatima za fizičku komponentu, psihološku komponentu-izgled te u globalnom rezultatu za skupinu koja je primala 60 mg, te u podrezultatu za fizičku komponentu u skupini koja je primala 40 mg.
The recommended dose is one ampoule of Signifor 0.6 mg twice a day. 
Preporučena doza je jedna ampula Signifora 0,6 mg dvaput na dan.
Common (may affect up to 1 in 10 people) - Low cortisol levels. 
Često (mogu se javiti u manje od 1 na 10 osoba) - Niske razine kortizola.
Signifor solution for injection is filled in a break-off ampoule. 
Signifor otopina za injekciju nalazi se u ampuli čiji se vrh može odlomiti.
Following discontinuation of treatment with pasireotide, patients should be monitored until resolution. 
Nakon prekida liječenja pasireotidom, bolesnike treba pratiti dok se simptomi ne riješe.
Management of suspected adverse reactions or over-response to treatment (cortisol levels < lower limit of normal) may require dose reduction, interruption or discontinuation of Signifor. 
Za zbrinjavanje sumnji na nuspojave ili prekomjernog odgovora na liječenje (razine kortizola < donja granica normale) moglo bi biti potrebno smanjenje doze, privremeni prekid ili trajna obustava primjene Signifora.
Do not use Signifor if the solution is not clear or contains particles. 
Ne primjenjujte Signifor ako otopina nije bistra ili ako sadrži čestice.
Cushing's disease is caused by an enlargement in the pituitary gland (a gland at the base of the brain) called a pituitary adenoma. 
Cushingova bolest uzrokovana je povećanjem u hipofizi (žlijezdi koja se nalazi na donjoj strani mozga) koje se zove adenom hipofize.
Female patients of childbearing potential should be advised to use adequate contraception during treatment with Signifor (see section 4.6). 
Bolesnicama reproduktivne dobi treba savjetovati da upotrebljavaju odgovarajuću kontracepciju tijekom liječenja Signiforom (vidjeti dio 4.6).
Injection site reaction* 
Reakcija na mjestu primjene*
59.7% and 56% of patients in the pasireotide intramuscular use and octreotide intramuscular use treatment groups, respectively, were patients without previous pituitary surgery (de novo). 
59,7% bolesnika u skupini koja je primala pasireotid intramuskularno te 56% u skupini koja je primala oktreotid intramuskularno bili su bolesnici bez prethodne operacije hipofize (de novo).
How to inject Signifor 
Kako ubrizgati Signifor
Common (may affect up to 1 in 10 people) - Prolonged QT interval (an abnormal electrical signal in your heart that can be seen in tests) - Loss of appetite - Vomiting - Headache - Dizziness - Hair loss - Itching (pruritus) - Muscle pain (myalgia) - Joint pain (arthralgia) - Abnormal results of liver function tests - Abnormal results of pancreatic function tests - Abnormal blood coagulation properties 
Često (mogu se javiti u manje od 1 na 10 osoba) - Produženi QT interval (poremećen električni signal u Vašem srcu koji se može vidjeti na pretragama) - Gubitak apetita - Povraćanje - Glavobolja - Omaglica - Gubitak kose - Svrbež (pruritus) - Bolovi u mišićima (mijalgija) - Bolovi u zglobovima (artralgija) - Poremećeni rezultati testova jetrene funkcije - Poremećeni rezultati testova funkcije gušterače
There are no clinical data available on switching from the intramuscular to the subcutaneous pasireotide formulation. 
Ne postoje dostupni klinički podaci o prelasku s intramuskularne na supkutanu formulaciju pasireotida.
Self monitoring of blood glucose and/or FPG assessments should be done weekly for the first three months and periodically thereafter, as clinically appropriate, as well as over the first four to six weeks after any dose increase. 
Bolesnici trebaju sami pratiti glukozu u krvi i/ili obavljati pretrage FPG-a tjedno tijekom prva tri mjeseca te periodički nakon toga, kako je klinički potrebno, kao i tijekom prvih četiri do šest tjedana nakon svakog povećanja doze.
Very common (may affect more than 1 in 10 people) - Diarrhoea - Nausea - Stomach pain - Pain at the injection site 
Vrlo često (mogu se javiti u više od 1 na 10 osoba) - Proljev - Mučnina - Bolovi u trbuhu - Bol na mjestu primjene injekcije
Uncommon (may affect up to 1 in 100 people) - Change in pancreatic function blood test results (amylase) - Abnormal blood coagulation properties 
Manje često (mogu se javiti u manje od 1 na 100 osoba) - Promjena u rezultatima pretraga krvi za funkciju gušterače (amilaza) - Poremećena svojstva zgrušavanja krvi
Monitoring of pituitary function (e.g. TSH/free T4) before and periodically during Signifor therapy should therefore be considered, as clinically appropriate. 
Stoga treba razmotriti praćenje funkcije hipofize (npr. TSH/slobodni T4) prije i periodički tijekom terapije Signiforom, kako je klinički potrebno.
In study C2402, grade 3 elevated fasting glucose levels were reported in 14.3% and 17.7% of acromegaly patients treated with pasireotide intramuscular use 40 mg and 60 mg respectively, and in no patients in the active control group. 
U ispitivanju C2402, povišene razine glukoze natašte stupnja 3 bile su prijavljene u 14,3% odnosno 17,7% bolesnika s akromegalijom liječenih s 40 mg odnosno 60 mg pasireotida primijenjenog intramuskularno te ni u jednog bolesnika u skupini s aktivnom kontrolom.
The most common adverse reactions (incidence ≥1/10) in the phase III study G2304 were hyperglycaemia, diarrhoea, cholelithiasis and diabetes mellitus. 
Najčešće nuspojave (incidencija ≥1/10) u ispitivanju G2304 faze III bile su hiperglikemija, proljev, kolelitijaza i šećerna bolest.
Rare cases of concurrent elevations in ALT greater than 3 x ULN and bilirubin greater than 2 x ULN have been observed. 
Bili su opaženi rijetki slučajevi istodobnih povišenja ALT-a većih od 3 x GGN i bilirubina većih od 2 x GGN.
The responder rate at month 12 was comparable to month 6, with 13.4% and 25.0% in the 0.6 mg and 0.9 mg twice-daily groups, respectively. 
Stopa odgovora u 12. mjesecu bila je usporediva s onom u 6. mjesecu, s 13,4% odnosno 25,0% u skupini koja je primala 0,6 mg odnosno 0,9 mg dvaput na dan.
Injection site reaction includes injection site pain, injection site nodule, injection site discomfort, injection site bruising, injection site pruritus, injection site reaction, injection site hypersensitivity and injection site swelling. 
Reakcija na mjestu primjene injekcije uključuje bol na mjestu primjene, kvržicu na mjestu primjene, nelagodu na mjestu primjene, stvaranje modrica na mjestu primjene, pruritus na mjestu primjene, reakciju na mjestu primjene, preosjetljivost na mjestu primjene i oticanje na mjestu primjene injekcije.
The efficacy of pasireotide intramuscular use has been demonstrated in two phase III, multicentre studies in acromegaly patients and in one phase III, multicentre study in Cushing's disease patients. 
Djelotvornost pasireotida primijenjenog intramuskularno dokazana je u dva multicentrična ispitivanja faze III u bolesnika s akromegalijom te u jednom multicentričnom ispitivanju faze III u bolesnika s Cushingovom bolešću.
Age has been found to be a covariate in the population pharmacokinetic analysis of Cushing's disease patients. 
Pokazalo se da je dob kovarijabla u farmakokinetičkoj analizi populacije bolesnika s Cushingovom bolešću.
A phase III, multicentre, randomised study was conducted to evaluate the safety and efficacy of different dose levels of Signifor over a twelve-month treatment period in Cushing's disease patients with persistent or recurrent disease or de novo patients for whom surgery was not indicated or who refused surgery. 
Multicentrično, randomizirano ispitivanje faze III bilo je provedeno da bi se procijenila sigurnost i djelotvornost različitih doza Signifora tijekom razdoblja liječenja od 12 mjeseci kod bolesnika s perzistentnom ili rekurentnom Cushingovom bolešću, ili kod de novo bolesnika u kojih kirurški zahvat nije bio indiciran ili koji su odbili kirurški zahvat.
Each unit pack contains the vial and pre-filled syringe in a sealed blister tray with one vial adapter and one safety-engineered needle for injection. 
Svako jedinično pakiranje sadrži bočicu i napunjenu štrcaljku u zatvorenom podlošku s jednim nastavkom za bočicu i jednom iglom za injekciju sa zaštitnim mehanizmom.
Acromegaly The recommended initial dose for the treatment of acromegaly is 40 mg of pasireotide every 4 weeks. 
Akromegalija Preporučena početna doza za liječenje akromegalije je 40 mg pasireotida svaka 4 tjedna.
Patients were randomised in a 1:1 ratio to a starting dose of either 10 mg or 30 mg pasireotide intramuscular use every 4 weeks. 
Bolesnici su bili randomizirani u omjeru 1:1 na primanje početne doze od 10 mg ili 30 mg pasireotida primijenjenog intramuskularno svaka 4 tjedna.
- Problems with bile flow (cholestasis). 
- Problemi s protokom žuči (kolestaza).
Acromegaly study C2402, inadequately controlled patients Study C2402 was a phase III, multicentre, randomised, parallel-group, three-arm study of double-blind pasireotide intramuscular use 40 mg and 60 mg versus open-label octreotide intramuscular use 30 mg or lanreotide deep subcutaneous injection 120 mg in patients with inadequately controlled acromegaly. 
Ispitivanje u bolesnika s akromegalijom C2402, neodgovarajuće kontrolirani bolesnici Ispitivanje C2402 bilo je multicentrično, randomizirano ispitivanje faze III s tri paralelne skupine u kojem se ispitivao dvostruko slijepi pasireotid 40 mg i 60 mg primijenjen intramuskularno u usporedbi s otvorenim ispitivanjem u kojem se primjenjivao oktreotid 30 mg intramuskularno ili lanreotid 120 mg dubokom supkutanom injekcijom u bolesnika s neodgovarajuće kontroliranom akromegalijom.
Self monitoring of blood glucose and/or FPG assessments should be done weekly for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase. 
Bolesnici trebaju sami pratiti glukozu u krvi i/ili obavljati pretrage FPG-a tjedno tijekom prva dva ili tri mjeseca te periodički nakon toga, kako je klinički potrebno, kao i tijekom prva dva do četiri tjedna nakon svakog povećanja doze.
As the pharmacological activity of pasireotide mimics that of somatostatin, inhibition of pituitary hormones other than ACTH cannot be ruled out. 
Budući da farmakološka aktivnost pasireotida oponaša aktivnost somatostatina, ne može se isključiti inhibicija i drugih hormona hipofize pored ACTH-a.
Coagulation abnormalities 
Abnormalnosti u koagulaciji
<2.5 µg/l and normalisation of IGF-1 at the same time point was also comparable between the two treatment arms. 
Postotak bolesnika koji su imali srednje vrijednosti GH-a <2,5 µg/l i normalizaciju IGF-1 u istoj vremenskoj točki također je bio usporediv između dviju terapijskih skupina.
The European Medicines Agency has waived the obligation to submit the results of studies with Signifor in all subsets of the paediatric population in pituitary-dependant Cushing's disease, overproduction of pituitary ACTH and pituitary dependant hyperadrenocorticism (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Signifor u svim podskupinama pedijatrijske populacije u Cushingovoj bolesti ovisnoj o hipofizi, prekomjernoj proizvodnji ACTH-a u hipofizi i hiperadrenokorticizmu ovisnom o hipofizi (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Cholecystitis *, cholestasis 
Kolecistitis*, kolestaza
The proportion of patients with a reduction or no change in pituitary tumour volume at week 24 was 81.0% and 70.3% on pasireotide intramuscular use 40 and 60 mg, and 50.0% on active control. 
Udio bolesnika sa smanjenjem ili bez promjene volumena tumora hipofize u 24. tjednu bio je 81,0% odnosno 70,3% uz pasireotid 40 odnosno 60 mg primijenjen intramuskularno, te 50,0% uz aktivnu kontrolu.
Cholelithiasis is a recognised adverse reaction associated with long-term use of somatostatin analogues and has frequently been reported in clinical studies with pasireotide (see section 4.8). 
Kolelitijaza je poznata nuspojava povezana s dugoročnom uporabom analoga somatostatina i često se prijavljuje u kliničkim ispitivanjima s pasireotidom (vidjeti dio 4.8).
The efficacy and safety of pasireotide intramuscular use was evaluated in a phase III, multicentre study over a 12-month treatment period in Cushing's disease patients with persistent or recurrent disease or de novo patients for whom surgery was not indicated or who refused surgery. 
Djelotvornost i sigurnost pasireotida primijenjenog intramuskularno ocjenjivala se u multicentričnom ispitivanju faze III tijekom 12-mjesečnog razdoblja liječenja u bolesnika s Cushingovom bolešću koji su imali perzistentnu ili rekurentnu bolest ili u de novo bolesnika za koje kirurški zahvat nije bio indiciran ili koji su ga odbili.
Signifor should be administered using sterile disposable syringes and injection needles. 
Signifor treba primjenjivati koristeći sterilne štrcaljke i igle za injekcije za jednokratnu uporabu.
In a clinical study of a single subcutaneous dose of pasireotide in subjects with impaired hepatic function, statistically significant differences were found in subjects with moderate and severe hepatic impairment (Child-Pugh B and C). 
U kliničkom ispitivanju s jednokratnom supkutanom dozom pasireotida u ispitanika s oštećenom funkcijom jetre pronađene su statistički značajne razlike u ispitanika s umjerenim i teškim oštećenjem jetre (Child-Pugh B i C).
Secondary end-points included, among others, changes from baseline in: 24-hour UFC, plasma ACTH, serum cortisol levels, and clinical signs and symptoms of Cushing's disease. 
Sekundarne mjere ishoda uključivale su, između ostaloga, promjene od početne vrijednosti u: 24-satnom UFC-u, ACTH-u u plazmi, razinama kortizola u serumu, te kliničkim znakovima i simptomima Cushingove bolesti.
Cushings disease: the recommended initial dose for Cushing's disease patients with moderate hepatic impairment (Child Pugh B) is 10 mg every 4 weeks, and the maximum recommended dose for these patients is 20 mg every 4 weeks (see section 5.2). 
Cushingova bolest: preporučena početna doza za bolesnike s Cushingovom bolešću i s umjerenim oštećenjem jetre (Child Pugh B) iznosi 10 mg svaka 4 tjedna, a najveća preporučena doza za te bolesnike je 20 mg svaka 4 tjedna (vidjeti dio 5.2).
Secondary end points included changes from baseline in: 24-hour UFC, plasma ACTH, serum cortisol levels, and clinical signs and symptoms of Cushing's disease. 
Mjere sekundarnog ishoda uključivale su promjene u odnosu na početnu vrijednost: 24-satnog UFC-a, ACTH-a u plazmi, razina kortizola u serumu i kliničkih znakova i simptoma Cushingove bolesti.
The solvent is a clear, colourless to slightly yellow or slightly brown solution in a pre-filled syringe. 
Otapalo je bistra, bezbojna do blago žuta ili blago smeđa otopina u napunjenoj štrcaljki.
Acromegaly: the recommended initial dose for acromegaly patients with moderate hepatic impairment (Child Pugh B) is 20 mg every 4 weeks, and the maximum recommended dose for these patients is 40 mg every 4 weeks (see section 5.2). 
Akromegalija: preporučena početna doza za bolesnike s akromegalijom i s umjerenim oštećenjem jetre (Child Pugh B) iznosi 20 mg svaka 4 tjedna (vidjeti dio 5.2), a najveća preporučena doza za te bolesnike je 40 mg svaka 4 tjedna (vidjeti dio 5.2).
Improvements were observed in both dose groups for CushingQoL and the Mental Component Summary (MCS) of SF-12v2, but not for the Physical Component Summary (PCS) of SF-12v2. 
Mental Component Summary), ali ne i prema PCS u SF-12v2 (eng.
Acromegaly 
Akromegalija
Dose reduction by decrements of 0.3 mg twice a day is suggested. 
Preporučuje se smanjenje doze za po 0,3 mg dvaput na dan.
Most patients (83.3%) had persistent or recurrent Cushing's disease and few (≤5%) in either treatment group had received previous pituitary irradiation. 
Većina bolesnika (83,3%) imala je perzistentnu ili rekurentnu Cushingovu bolest, a u nekoliko bolesnika (≤5%) u svakoj od terapijskih skupina prethodno je primijenjeno zračenje hipofize.
Monitoring of blood glucose levels in patients treated with Signifor is recommended (see section 4.4). 
Kod bolesnika liječenih Signiforom preporučuje se praćenje razina glukoze u krvi (vidjeti dio 4.4).
(hypoglycaemia); - heart problems such as a recent heart attack, congestive heart failure (a type of heart disease where the heart cannot pump enough blood around the body) or sudden and oppressive chest pain (usually felt as pressure, heaviness, tightening, squeezing or aching across the chest); - a heart rhythm disorder, such as an irregular heartbeat or an abnormal electrical signal called 
(hipoglikemija), - srčane probleme kao što su nedavni srčani udar, kongestivno zatajenje srca (vrsta srčane bolesti kod koje srce ne može pumpati dovoljno krvi po tijelu) ili iznenadna i teška bol u grudnom košu
The recommended initial dose for the treatment of Cushing's disease is 10 mg of pasireotide by deep intramuscular injection every 4 weeks. 
Preporučena početna doza za liječenje Cushingove bolesti je 10 mg pasireotida dubokom intramuskularnom injekcijom svaka 4 tjedna.
Pasireotide should be used with caution in patients who are concomitantly receiving medicinal products that prolong the QT interval, such as class Ia antiarrhythmics (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmics (e.g. amiodarone, dronedarone, sotalol, dofetilide, ibutilide), certain antibacterials (intravenous erythromycin, pentamidine injection, clarithromycin, moxifloxacin), certain antipsychotics (e.g. chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol, tiapride, amisulpride, sertindole, methadone), certain antihistamines (e.g. terfenadine, astemizole, mizolastine), antimalarials (e.g. chloroquine, halofantrine, lumefantrine), certain antifungals (ketoconazole, except in shampoo) (see also section 4.4). 
Pasireotid treba oprezno koristiti kod bolesnika koji istodobno primaju lijekove koji produžuju QT interval, kao što su antiaritmici klase Ia (npr. kinidin, prokainamid, dizopiramid), antiaritmici klase III (npr. amiodaron, dronedaron, sotalol, dofetilid, ibutilid), određeni antibiotici (intravenski eritromicin, injekcija pentamidina, klaritromicin, moksifloksacin), određeni antipsihotici (npr. klorpromazin, tioridazin, flufenazin, pimozid, haloperidol, tiaprid, amisulpirid, sertindol, metadon), određeni antihistaminici (npr. terfenadin, astemizol, mizolastin), antimalarici (npr. klorokin, halofantrin, lumefantrin), određeni antimikotici (ketokonazol, osim u šamponu) (vidjeti također dio 4.4).
Signifor is to be administered subcutaneously by self injection. 
Signifor se primjenjuje supkutano samoubrizgavanjem.